Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report released on Monday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 5.2 %

Shares of AXDX opened at $1.09 on Monday. Accelerate Diagnostics has a twelve month low of $0.73 and a twelve month high of $2.09. The firm’s fifty day simple moving average is $1.17 and its 200-day simple moving average is $1.47. The firm has a market capitalization of $27.30 million, a price-to-earnings ratio of -0.38 and a beta of 0.55.

Institutional Investors Weigh In On Accelerate Diagnostics

Several hedge funds and other institutional investors have recently bought and sold shares of AXDX. Renaissance Technologies LLC raised its stake in Accelerate Diagnostics by 160.6% during the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after acquiring an additional 65,984 shares in the last quarter. Jane Street Group LLC acquired a new stake in Accelerate Diagnostics during the 4th quarter worth $27,000. Y Intercept Hong Kong Ltd acquired a new stake in Accelerate Diagnostics during the 3rd quarter worth $34,000. Finally, Geode Capital Management LLC raised its stake in Accelerate Diagnostics by 6.9% during the 4th quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock worth $163,000 after acquiring an additional 8,777 shares in the last quarter. 17.14% of the stock is currently owned by institutional investors and hedge funds.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.